LivaNova (NASDAQ:LIVN - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 3.600-3.700 for the period, compared to the consensus earnings per share estimate of 3.580. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.
LivaNova Stock Performance
NASDAQ:LIVN traded up $1.30 during mid-day trading on Monday, hitting $45.36. 462,598 shares of the company traded hands, compared to its average volume of 732,279. The stock's fifty day moving average price is $37.89 and its 200-day moving average price is $45.09. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of 108.00 and a beta of 0.84. LivaNova has a one year low of $32.48 and a one year high of $63.57. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.
Wall Street Analyst Weigh In
Several brokerages have commented on LIVN. The Goldman Sachs Group decreased their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Robert W. Baird boosted their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday. Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. Finally, StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, LivaNova currently has an average rating of "Moderate Buy" and an average price target of $59.17.
Get Our Latest Stock Report on LIVN
About LivaNova
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Stories
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
